丹皮酚增强顺铂对人食管癌细胞Eca-109的抗肿瘤作用

Synergistic anti-tumor effect of paeonol and cisplatin on human esophageal cancer cell line Eca-109

目的探讨丹皮酚联合顺铂在体内外应用对人食管癌细胞Eca-109的抑制作用。方法采用MTT体外试验法和裸鼠移植瘤动物模型体内试验法研究两药的抗肿瘤作用,两药相互作用指数(CDI)评价联合用药性质。结果丹皮酚在体外可明显抑制Eca-109细胞增殖,其IC50为124·77mg/L;不同浓度的丹皮酚与顺铂联用时抑制率较单一用药时显著提高,差异具有显著性,采用两药相互作用指数分析,丹皮酚7·81、15·63、31·25mg/L与系列浓度(0·078～2·5mg/L)的顺铂联合用药时具有协同作用(CDI<1)。体内灌胃给予丹皮酚25、50、100、200mg/kg对裸鼠移植人食管癌Eca-109的抑制率分别为10·67%、23·54%、27·91%、34·46%;丹皮酚在100mg/kg剂量下与顺铂5mg/kg联合用药抑制率为77·91%,与单一用药时比较差异有显著性(P<0·05),CDI=0·74。结论丹皮酚对人食管癌细胞Eca-109有抗肿瘤作用,与顺铂联合应用具有明显的协同作用。

Objective To investigate the synergistic suppressive effect of paeonol and cisplatin on human esophageal cancer cell line Eca-109 in vitro and vivo. Methods The anti-tumor effect was evaluated by MTT assay in vitro and nude mice implanted Eca-109 cancer cell in vivo. The coefficient of drug interaction（CDI） was used to analyse the synergistic inhibitory effect of drug combination. Results Paeonol had markedly inhibitory effect on the proliferation of Eca-109 cell line at IC50 of 124. 77 mg/L. The inhibition ratio of Eca-109 treated with combined agents were significantly higher than those treated with paeonol and cisplatin alone, and the variance was significant. CDI showed that the combination of paeonol （7.81, 15.63, 31.25 mg/L） and cisplatin （0. 078 - 2. 5 mg/L） had synergistic inhibitory effects on Eca-109 （CDI 〈 1 ）. Under the dose of 25 -200 mg/kg, the inhibition ratio of paeonol on Eca-109 in BALB/c nude mice were 10. 67%, 23.54%, 27.91% and 34. 46% respectivity;the inhibition ratio of paeonol（ 100 mg/kg）combined with cisplatin（5 mg/kg）was 77.91%, had significant difference as compared with those treated with drug alone （ P 〈 0. 05 ）, and CDI = 0. 74. Conclusion Paeonol has anti - tumor effect on human esophageal cancer cell Eca-109, moreover, it＇s combination with cisplatin has significantly synergistic inhibitory effect on Eca-109.